Navigation Links
Childers, Schlueter & Smith, LLC Set for Reglan/metoclopramide Jury Trial Involving Woman's Development of Tardive Dyskinesia
Date:7/19/2010

ATLANTA, July 19 /PRNewswire/ -- The law firm of Childers, Schlueter & Smith, LLC of Atlanta, Georgia has announced that a jury trial involving the drug Reglan/metoclopramide will be held during the week of July 26, 2010.  The case is Susan Swicegood v. Pliva et. al. in the United States District Court, Northern District of Georgia, Atlanta Division.

The lawsuit alleges that the drug makers and marketers of Reglan/metoclopramide failed to adequately warn physicians of the long-term dangers associated with taking the drug, specifically, the neurological disorder tardive dyskinesia.

Reglan and its generic equivalent, metoclopramide, are used to treat several types of stomach disorders including nausea and acid reflux. The complaint alleges that Ms. Swicegood's doctor prescribed 10mg Reglan to be taken four times daily. Ms. Swicegood took the generic form of the drug and developed a permanent movement disorder called tardive dyskinesia as a result - a disorder of the nerves in which involuntary, repetitive movements develop in the lower portion of the face and in limbs.

Previous and Pending Reglan lawsuits, which now total over 150 filed, prompted the FDA to change requirements in the labeling of the drug in February 2009 to account for the increased risk of developing tardive dyskinesia from Reglan/metoclopramide use. New rules included a "Black Box" warning about the potential risk of tardive dyskinesia from long-term use. However, the suit alleges that the Physician's Desk Reference used by Ms. Swicegood's doctor was not updated with the new warnings as required by law.  As a result, neither the patient nor her doctor understood the true risk of taking or prescribing the drug.

The lawsuit was filed in the United States District Court, Northern District of Georgia, Atlanta Division. The Defendant in the case is Pliva, Inc. The Civil Action File Number is 1:07-CV-1671. Childers, Schlueter & Smith, LLC will conduct the Reglan/metoclopramide jury trial with its nationally renowned co-counsel of Daniel J. McGlynn of McGlynn, Glisson, and Mouton Law Firm and Bill Curtis of Miller, Curtis & Weisbrod, LLP.

About Childers, Schlueter & Smith:

Childers, Schlueter & Smith is a preeminent Georgia law firm that takes pride in years of experience and exceptional results. For more about the alleged dangers of Reglan/metoclopramide, or to learn more about Childers, Schlueter & Smith, call toll free at 1-800-641-0098 or visit http://www.cssfirm.com.


'/>"/>
SOURCE Childers, Schlueter & Smith, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Frost & Sullivan: Western European Markets Confirm Undisputed Convenience and Cost Benefit of Custom Procedure Trays
2. Boston Scientific and Johnson & Johnson Announce Settlement of Patent Disputes
3. Tata Interactive Systems Partners With Bersin & Associates for Exclusive Executive Learning Forum - TLF 2009
4. Sigma-Aldrich (Nasdaq: SIAL) Announces Appointment of George Miller as Sr. Vice President, General Counsel & Secretary
5. Robbins & Myers Announces Regular Quarterly Cash Dividend
6. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
7. Frost & Sullivan Lauds Viatronix as European Medical Imaging Emerging Company of the Year
8. Bausch & Lomb Acquires the Commercial Assets of Italian Ophthalmic Pharmaceuticals Company Tubilux
9. Robbins & Myers Announces Fourth Quarter and Full Year 2009 Results
10. Dynatronics Appoints Douglas Sampson as Vice President of Production and Research & Development
11. Frost & Sullivan Identifies Focus on Quality Management and Adoption of a Full-service Model as Keys to the Growth of the European CRO Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... NeuroRx, a clinical stage biopharma company developing the ... has been granted Fast Track status by the US Food ... HCl) followed by NRX-101 (D-cycloserine + lurasidone). The company will ... sequential therapy targeting patients who are admitted to Emergency Departments ... ...
(Date:9/5/2017)... 2017  Just 18 months after its February 2016 ... announce the appointment of three new senior people to ... Dominic Jones-Phillips and James Wright bring ... Tammy Wynne joins as ... writers. She has over ten years, experience in global ...
(Date:8/31/2017)... YORK , Aug. 31, 2017 PM360,s ... industry,s must-read guide to the latest innovations happening across ... first industry publication to focus on providing a comprehensive ... Ultimately, the issue covers the most innovative companies, startups, ... "Everyone in this ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... September 20, 2017 , ... ... medical device compliance and commercialization, has just released a new white paper ... is more adamant than ever about medical device, pharmaceutical, and combination product ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... and industry-leading compliance software, The Guard®, has helped another long-time client pass their ... audit and properly satisfy the law. , Thanks to the help of the ...
(Date:9/20/2017)... ... , ... The Centers for Medicare and Medicaid Services (CMS) stated in the ... only Worksheet S-10 to distribute Disproportionate Share Hospital (DSH) Uncompensated Care Payments over the ... on October 17, 2017 at 2 P.M. EST and uncover how you can ...
(Date:9/20/2017)... ... 2017 , ... “RECYCLED Ezekiel's Plan for Freedom from ADDICTION”: ... ADDICTION” is the creation of published author, Bill Miller. Bill Miller has ... including more than a decade of addiction to prescription drugs. He has ...
(Date:9/20/2017)... ... , ... “The Foggy Road to Moorwick”: the adventures of a young Scottish girl yearning to ... Jeanine Liston, a busy mother of five who used her time waiting for children to ... for over twenty years. It was a way to give some meaning to the ...
Breaking Medicine News(10 mins):